SAMN03290890
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- GLYCOLYSIS+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- SPERMATOGENESIS+0.300
- HYPOXIA+0.200
- MYC_TARGETS_V1+0.200
- PANCREAS_BETA_CELLS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- TGF_BETA_SIGNALING-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- APOPTOSIS-0.200
- BILE_ACID_METABOLISM-0.200
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043634 | — | — | 0.822 |
| 2 | 7153b1ef-41b9-4b43-a766-0910291502dd | — | — | 0.817 |
| 3 | TCGA-OR-A5JA-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.773 |
| 4 | R397 | — | — | 0.771 |
| 5 | MNG592 | — | — | 0.769 |
| 6 | TCGA-4Z-AA84-01A-11R-A39I-07 | — | — | 0.750 |
| 7 | MNG798 | — | — | 0.749 |
| 8 | MDT-AP-3082 | Med | Medulloblastoma | 0.748 |
| 9 | SRR6013537 | — | cohortA3 | 0.746 |
| 10 | TCGA-KU-A66T-01A-11R-A30B-07 | — | — | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |